# Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

> **NCT06109207** · PHASE1 · RECRUITING · sponsor: **West China Hospital** · enrollment: 6 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Dalpiciclib 100mg
- **DRUG:** Dalpiciclib 150mg

## Key facts

- **NCT ID:** NCT06109207
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-31
- **Primary completion:** 2024-10-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2024-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06109207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06109207, "Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06109207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*